CCT301-59 / Sunterra Biotech, Exuma Biotech - LARVOL DELTA

Safety and Efficacy of CCT301 CAR-T in Adult Subjects With Recurrent or Refractory Stage IV Renal Cell Carcinoma (clinicaltrials.gov) - P1/2 | N=66 | Terminated | Sponsor: Shanghai PerHum Therapeutics Co., Ltd. | Active, not recruiting ➔ Terminated; Adjustment of study strategy

Metastases • Trial termination • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • AXL • ROR2

A Study of CCT301-59 CAR T Therapy in Adult Subjects With Recurrent or Refractory Solid Tumors (clinicaltrials.gov) - P1 | N=9 | Terminated | Sponsor: Shanghai PerHum Therapeutics Co., Ltd. | N=18 ➔ 9 | Active, not recruiting ➔ Terminated; Adjustment of study strategy

Enrollment change • Trial termination • Bladder Cancer • Gastric Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Hepatocellular Cancer • Hepatology • Oncology • Pancreatic Cancer • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • ROR2

A Study of CCT301-59 CAR T Therapy in Adult Subjects With Recurrent or Refractory Solid Tumors (clinicaltrials.gov) - P1; N=18; Active, not recruiting; Sponsor: Shanghai PerHum Therapeutics Co., Ltd.; Trial primary completion date: Feb 2021 ➔ Jun 2022

Clinical • Trial primary completion date • Bladder Cancer • Gastric Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Hepatocellular Cancer • Hepatology • Oncology • Pancreatic Cancer • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • Urothelial Cancer

Safety and Efficacy of CCT301 CAR-T in Adult Subjects With Recurrent or Refractory Stage IV Renal Cell Carcinoma (clinicaltrials.gov) - P1/2; N=66; Active, not recruiting; Sponsor: Shanghai PerHum Therapeutics Co., Ltd.; Trial completion date: Mar 2035 ➔ Jun 2023; Trial primary completion date: Jan 2021 ➔ Jun 2022

Clinical • Trial completion date • Trial primary completion date • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • AXL

A Study of CCT301-59 CAR T Therapy in Adult Subjects With Recurrent or Refractory Solid Tumors (clinicaltrials.gov) - P1; N=18; Active, not recruiting; Sponsor: Shanghai PerHum Therapeutics Co., Ltd.; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed • Bladder Cancer • Gastric Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Hepatocellular Cancer • Oncology • Pancreatic Cancer • Sarcoma • Solid Tumor • Urothelial Cancer

Safety and Efficacy of CCT301 CAR-T in Adult Subjects With Recurrent or Refractory Stage IV Renal Cell Carcinoma (clinicaltrials.gov) - P1/2; N=66; Active, not recruiting; Sponsor: Shanghai Sinobioway Sunterra Biotech; Recruiting ➔ Active, not recruiting

Enrollment closed